nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—HSD3B2—polycystic ovary syndrome	0.295	0.389	CbGaD
Medroxyprogesterone Acetate—AKR1C3—polycystic ovary syndrome	0.164	0.215	CbGaD
Medroxyprogesterone Acetate—PGR—polycystic ovary syndrome	0.091	0.12	CbGaD
Medroxyprogesterone Acetate—SHBG—polycystic ovary syndrome	0.085	0.112	CbGaD
Medroxyprogesterone Acetate—AR—polycystic ovary syndrome	0.0745	0.0981	CbGaD
Medroxyprogesterone Acetate—NR3C1—polycystic ovary syndrome	0.0506	0.0665	CbGaD
Medroxyprogesterone Acetate—HSD3B2—ovarian follicle—polycystic ovary syndrome	0.0216	0.265	CbGeAlD
Medroxyprogesterone Acetate—PGR—corpus luteum—polycystic ovary syndrome	0.00788	0.0967	CbGeAlD
Medroxyprogesterone Acetate—PGR—ovarian follicle—polycystic ovary syndrome	0.00616	0.0757	CbGeAlD
Medroxyprogesterone Acetate—Abdominal distress—Metformin—polycystic ovary syndrome	0.00566	0.176	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—ovarian follicle—polycystic ovary syndrome	0.00482	0.0592	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—adrenal cortex—polycystic ovary syndrome	0.00239	0.0293	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—pituitary gland—polycystic ovary syndrome	0.00193	0.0237	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—adrenal gland—polycystic ovary syndrome	0.00172	0.0212	CbGeAlD
Medroxyprogesterone Acetate—Abdominal bloating—Metformin—polycystic ovary syndrome	0.00161	0.0499	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—female gonad—polycystic ovary syndrome	0.00161	0.0197	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—endocrine gland—polycystic ovary syndrome	0.0015	0.0184	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—urine—polycystic ovary syndrome	0.00149	0.0183	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—urine—polycystic ovary syndrome	0.00147	0.0181	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—urine—polycystic ovary syndrome	0.00112	0.0138	CbGeAlD
Medroxyprogesterone Acetate—Heartburn—Metformin—polycystic ovary syndrome	0.00111	0.0346	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—adrenal cortex—polycystic ovary syndrome	0.00101	0.0124	CbGeAlD
Medroxyprogesterone Acetate—Blood disorder—Metformin—polycystic ovary syndrome	0.000917	0.0285	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—endometrium—polycystic ovary syndrome	0.0009	0.0111	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—uterus—polycystic ovary syndrome	0.000829	0.0102	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—pituitary gland—polycystic ovary syndrome	0.000814	0.01	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—adipose tissue—polycystic ovary syndrome	0.000811	0.00996	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—adrenal gland—polycystic ovary syndrome	0.000728	0.00894	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—female gonad—polycystic ovary syndrome	0.000678	0.00833	CbGeAlD
Medroxyprogesterone Acetate—SHBG—endometrium—polycystic ovary syndrome	0.000677	0.00831	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—vagina—polycystic ovary syndrome	0.000674	0.00828	CbGeAlD
Medroxyprogesterone Acetate—ESR1—embryo—polycystic ovary syndrome	0.000651	0.008	CbGeAlD
Medroxyprogesterone Acetate—SHBG—uterus—polycystic ovary syndrome	0.000623	0.00766	CbGeAlD
Medroxyprogesterone Acetate—SHBG—pituitary gland—polycystic ovary syndrome	0.000612	0.00752	CbGeAlD
Medroxyprogesterone Acetate—SHBG—adipose tissue—polycystic ovary syndrome	0.00061	0.00749	CbGeAlD
Medroxyprogesterone Acetate—PGR—endometrium—polycystic ovary syndrome	0.000609	0.00749	CbGeAlD
Medroxyprogesterone Acetate—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00057	0.0177	CcSEcCtD
Medroxyprogesterone Acetate—PGR—uterus—polycystic ovary syndrome	0.000562	0.0069	CbGeAlD
Medroxyprogesterone Acetate—Pain in extremity—Metformin—polycystic ovary syndrome	0.000556	0.0173	CcSEcCtD
Medroxyprogesterone Acetate—PGR—pituitary gland—polycystic ovary syndrome	0.000552	0.00677	CbGeAlD
Medroxyprogesterone Acetate—PGR—adipose tissue—polycystic ovary syndrome	0.000549	0.00675	CbGeAlD
Medroxyprogesterone Acetate—Migraine—Metformin—polycystic ovary syndrome	0.000547	0.017	CcSEcCtD
Medroxyprogesterone Acetate—SHBG—adrenal gland—polycystic ovary syndrome	0.000547	0.00672	CbGeAlD
Medroxyprogesterone Acetate—AR—adrenal cortex—polycystic ovary syndrome	0.000544	0.00668	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female gonad—polycystic ovary syndrome	0.00051	0.00626	CbGeAlD
Medroxyprogesterone Acetate—SHBG—vagina—polycystic ovary syndrome	0.000507	0.00623	CbGeAlD
Medroxyprogesterone Acetate—Breast disorder—Metformin—polycystic ovary syndrome	0.000502	0.0156	CcSEcCtD
Medroxyprogesterone Acetate—Cramp muscle—Metformin—polycystic ovary syndrome	0.000501	0.0155	CcSEcCtD
Medroxyprogesterone Acetate—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.000497	0.0154	CcSEcCtD
Medroxyprogesterone Acetate—PGR—adrenal gland—polycystic ovary syndrome	0.000493	0.00605	CbGeAlD
Medroxyprogesterone Acetate—AR—endometrium—polycystic ovary syndrome	0.000486	0.00596	CbGeAlD
Medroxyprogesterone Acetate—Abdominal distension—Metformin—polycystic ovary syndrome	0.000484	0.015	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—embryo—polycystic ovary syndrome	0.000481	0.0059	CbGeAlD
Medroxyprogesterone Acetate—Influenza—Metformin—polycystic ovary syndrome	0.00048	0.0149	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—endometrium—polycystic ovary syndrome	0.000477	0.00586	CbGeAlD
Medroxyprogesterone Acetate—SHBG—endocrine gland—polycystic ovary syndrome	0.000474	0.00583	CbGeAlD
Medroxyprogesterone Acetate—Sweating increased—Metformin—polycystic ovary syndrome	0.000468	0.0145	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000461	0.0143	CcSEcCtD
Medroxyprogesterone Acetate—PGR—female gonad—polycystic ovary syndrome	0.000459	0.00564	CbGeAlD
Medroxyprogesterone Acetate—PGR—vagina—polycystic ovary syndrome	0.000457	0.00561	CbGeAlD
Medroxyprogesterone Acetate—AR—uterus—polycystic ovary syndrome	0.000447	0.0055	CbGeAlD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000447	0.0139	CcSEcCtD
Medroxyprogesterone Acetate—AR—pituitary gland—polycystic ovary syndrome	0.000439	0.0054	CbGeAlD
Medroxyprogesterone Acetate—ESR1—uterus—polycystic ovary syndrome	0.000439	0.0054	CbGeAlD
Medroxyprogesterone Acetate—AR—adipose tissue—polycystic ovary syndrome	0.000438	0.00538	CbGeAlD
Medroxyprogesterone Acetate—ESR1—pituitary gland—polycystic ovary syndrome	0.000431	0.0053	CbGeAlD
Medroxyprogesterone Acetate—ESR1—adipose tissue—polycystic ovary syndrome	0.00043	0.00528	CbGeAlD
Medroxyprogesterone Acetate—Drowsiness—Metformin—polycystic ovary syndrome	0.000428	0.0133	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Metformin—polycystic ovary syndrome	0.000428	0.0133	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Metformin—polycystic ovary syndrome	0.000428	0.0133	CcSEcCtD
Medroxyprogesterone Acetate—PGR—endocrine gland—polycystic ovary syndrome	0.000427	0.00525	CbGeAlD
Medroxyprogesterone Acetate—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00042	0.013	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000405	0.0126	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—adrenal cortex—polycystic ovary syndrome	0.000394	0.00484	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—endometrium—polycystic ovary syndrome	0.000393	0.00482	CbGeAlD
Medroxyprogesterone Acetate—AR—adrenal gland—polycystic ovary syndrome	0.000393	0.00482	CbGeAlD
Medroxyprogesterone Acetate—Bradycardia—Metformin—polycystic ovary syndrome	0.000392	0.0122	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—adrenal gland—polycystic ovary syndrome	0.000385	0.00473	CbGeAlD
Medroxyprogesterone Acetate—Hepatitis—Metformin—polycystic ovary syndrome	0.000385	0.0119	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000379	0.0118	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000378	0.0117	CcSEcCtD
Medroxyprogesterone Acetate—Cyproterone acetate—AR—polycystic ovary syndrome	0.000373	0.0662	CrCbGaD
Medroxyprogesterone Acetate—AR—female gonad—polycystic ovary syndrome	0.000366	0.0045	CbGeAlD
Medroxyprogesterone Acetate—AR—vagina—polycystic ovary syndrome	0.000364	0.00447	CbGeAlD
Medroxyprogesterone Acetate—Dydrogesterone—PGR—polycystic ovary syndrome	0.000361	0.0642	CrCbGaD
Medroxyprogesterone Acetate—Eye disorder—Metformin—polycystic ovary syndrome	0.000359	0.0112	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—female gonad—polycystic ovary syndrome	0.000359	0.00441	CbGeAlD
Medroxyprogesterone Acetate—ESR1—vagina—polycystic ovary syndrome	0.000357	0.00439	CbGeAlD
Medroxyprogesterone Acetate—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000357	0.0111	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—pituitary gland—polycystic ovary syndrome	0.000355	0.00436	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—endometrium—polycystic ovary syndrome	0.000352	0.00432	CbGeAlD
Medroxyprogesterone Acetate—Angiopathy—Metformin—polycystic ovary syndrome	0.000349	0.0108	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Metformin—polycystic ovary syndrome	0.000347	0.0108	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000347	0.0108	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Metformin—polycystic ovary syndrome	0.000345	0.0107	CcSEcCtD
Medroxyprogesterone Acetate—AR—endocrine gland—polycystic ovary syndrome	0.00034	0.00418	CbGeAlD
Medroxyprogesterone Acetate—Malnutrition—Metformin—polycystic ovary syndrome	0.000335	0.0104	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Metformin—polycystic ovary syndrome	0.000335	0.0104	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—endocrine gland—polycystic ovary syndrome	0.000334	0.0041	CbGeAlD
Medroxyprogesterone Acetate—Flatulence—Metformin—polycystic ovary syndrome	0.00033	0.0102	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Metformin—polycystic ovary syndrome	0.000328	0.0102	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—uterus—polycystic ovary syndrome	0.000324	0.00398	CbGeAlD
Medroxyprogesterone Acetate—Muscle spasms—Metformin—polycystic ovary syndrome	0.000322	0.00999	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—pituitary gland—polycystic ovary syndrome	0.000318	0.00391	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—adipose tissue—polycystic ovary syndrome	0.000317	0.00389	CbGeAlD
Medroxyprogesterone Acetate—Tremor—Metformin—polycystic ovary syndrome	0.000314	0.00974	CcSEcCtD
Medroxyprogesterone Acetate—Cyproterone acetate—CYP19A1—polycystic ovary syndrome	0.000312	0.0554	CrCbGaD
Medroxyprogesterone Acetate—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000311	0.00964	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Metformin—polycystic ovary syndrome	0.000302	0.00937	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Metformin—polycystic ovary syndrome	0.0003	0.00932	CcSEcCtD
Medroxyprogesterone Acetate—Ethynodiol—PGR—polycystic ovary syndrome	0.000297	0.0529	CrCbGaD
Medroxyprogesterone Acetate—Palpitations—Metformin—polycystic ovary syndrome	0.000296	0.00919	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000294	0.00914	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—vagina—polycystic ovary syndrome	0.000294	0.00361	CbGeAlD
Medroxyprogesterone Acetate—Chest pain—Metformin—polycystic ovary syndrome	0.000285	0.00885	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Metformin—polycystic ovary syndrome	0.000285	0.00885	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—adrenal gland—polycystic ovary syndrome	0.000284	0.00349	CbGeAlD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000283	0.00879	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Metformin—polycystic ovary syndrome	0.000282	0.00874	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—endocrine gland—polycystic ovary syndrome	0.000275	0.00338	CbGeAlD
Medroxyprogesterone Acetate—Oedema—Metformin—polycystic ovary syndrome	0.000273	0.00848	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Metformin—polycystic ovary syndrome	0.000271	0.00843	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Metformin—polycystic ovary syndrome	0.000269	0.00835	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000268	0.00832	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000268	0.00831	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Metformin—polycystic ovary syndrome	0.000265	0.00824	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—female gonad—polycystic ovary syndrome	0.000265	0.00326	CbGeAlD
Medroxyprogesterone Acetate—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000264	0.0082	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—vagina—polycystic ovary syndrome	0.000263	0.00324	CbGeAlD
Medroxyprogesterone Acetate—Anorexia—Metformin—polycystic ovary syndrome	0.00026	0.00809	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Metformin—polycystic ovary syndrome	0.000255	0.00793	CcSEcCtD
Medroxyprogesterone Acetate—Cyproterone acetate—NR3C1—polycystic ovary syndrome	0.000253	0.0449	CrCbGaD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000249	0.00773	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—endocrine gland—polycystic ovary syndrome	0.000247	0.00303	CbGeAlD
Medroxyprogesterone Acetate—Paraesthesia—Metformin—polycystic ovary syndrome	0.000245	0.00762	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000245	0.003	CbGeAlD
Medroxyprogesterone Acetate—Dyspnoea—Metformin—polycystic ovary syndrome	0.000244	0.00756	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Metformin—polycystic ovary syndrome	0.000243	0.00754	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Metformin—polycystic ovary syndrome	0.000241	0.00747	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Metformin—polycystic ovary syndrome	0.000238	0.00737	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000236	0.00732	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Metformin—polycystic ovary syndrome	0.000236	0.00731	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Metformin—polycystic ovary syndrome	0.000234	0.00725	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000225	0.00699	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000223	0.00694	CcSEcCtD
Medroxyprogesterone Acetate—Megestrol acetate—PGR—polycystic ovary syndrome	0.000217	0.0386	CrCbGaD
Medroxyprogesterone Acetate—Urticaria—Metformin—polycystic ovary syndrome	0.000217	0.00674	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Metformin—polycystic ovary syndrome	0.000216	0.00671	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone Propionate—CYP17A1—polycystic ovary syndrome	0.000215	0.0382	CrCbGaD
Medroxyprogesterone Acetate—Asthenia—Metformin—polycystic ovary syndrome	0.000196	0.00609	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Metformin—polycystic ovary syndrome	0.000193	0.006	CcSEcCtD
Medroxyprogesterone Acetate—Drospirenone—PGR—polycystic ovary syndrome	0.00019	0.0337	CrCbGaD
Medroxyprogesterone Acetate—Diarrhoea—Metformin—polycystic ovary syndrome	0.000187	0.0058	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000186	0.00229	CbGeAlD
Medroxyprogesterone Acetate—Dizziness—Metformin—polycystic ovary syndrome	0.000181	0.00561	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Metformin—polycystic ovary syndrome	0.000174	0.00539	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Metformin—polycystic ovary syndrome	0.000172	0.00535	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Metformin—polycystic ovary syndrome	0.000172	0.00534	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Metformin—polycystic ovary syndrome	0.000171	0.00531	CcSEcCtD
Medroxyprogesterone Acetate—Prednicarbate—NR3C1—polycystic ovary syndrome	0.000163	0.0289	CrCbGaD
Medroxyprogesterone Acetate—Nausea—Metformin—polycystic ovary syndrome	0.000162	0.00504	CcSEcCtD
Medroxyprogesterone Acetate—Drospirenone—AR—polycystic ovary syndrome	0.000155	0.0276	CrCbGaD
Medroxyprogesterone Acetate—Fludrocortisone—AR—polycystic ovary syndrome	0.000146	0.026	CrCbGaD
Medroxyprogesterone Acetate—Fluoxymesterone—SHBG—polycystic ovary syndrome	0.000138	0.0245	CrCbGaD
Medroxyprogesterone Acetate—Medrysone—NR3C1—polycystic ovary syndrome	0.000136	0.0243	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—PGR—polycystic ovary syndrome	0.000135	0.024	CrCbGaD
Medroxyprogesterone Acetate—Flurandrenolide—NR3C1—polycystic ovary syndrome	0.000132	0.0234	CrCbGaD
Medroxyprogesterone Acetate—Testosterone Propionate—AR—polycystic ovary syndrome	0.00013	0.0232	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortamate—NR3C1—polycystic ovary syndrome	0.000127	0.0226	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—SHBG—polycystic ovary syndrome	0.000126	0.0224	CrCbGaD
Medroxyprogesterone Acetate—Cortisone acetate—NR3C1—polycystic ovary syndrome	0.000125	0.0223	CrCbGaD
Medroxyprogesterone Acetate—Fluoxymesterone—AR—polycystic ovary syndrome	0.000121	0.0215	CrCbGaD
Medroxyprogesterone Acetate—Megestrol acetate—NR3C1—polycystic ovary syndrome	0.000121	0.0215	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—SHBG—polycystic ovary syndrome	0.000111	0.0198	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—AR—polycystic ovary syndrome	0.000111	0.0197	CrCbGaD
Medroxyprogesterone Acetate—Fludrocortisone—NR3C1—polycystic ovary syndrome	9.93e-05	0.0176	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP17A1—polycystic ovary syndrome	9.86e-05	0.0175	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—AR—polycystic ovary syndrome	9.76e-05	0.0174	CrCbGaD
Medroxyprogesterone Acetate—Fluorometholone—NR3C1—polycystic ovary syndrome	9.57e-05	0.017	CrCbGaD
Medroxyprogesterone Acetate—Methylprednisolone—NR3C1—polycystic ovary syndrome	9.25e-05	0.0164	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP11A1—polycystic ovary syndrome	9.17e-05	0.0163	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—SHBG—polycystic ovary syndrome	8.38e-05	0.0149	CrCbGaD
Medroxyprogesterone Acetate—Fluoxymesterone—NR3C1—polycystic ovary syndrome	8.2e-05	0.0146	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—CYP19A1—polycystic ovary syndrome	8.17e-05	0.0145	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—NR3C1—polycystic ovary syndrome	7.51e-05	0.0133	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—PGR—polycystic ovary syndrome	7.31e-05	0.013	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—SHBG—polycystic ovary syndrome	6.83e-05	0.0121	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—SHBG—polycystic ovary syndrome	6.46e-05	0.0115	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—AR—polycystic ovary syndrome	5.99e-05	0.0106	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—AR—polycystic ovary syndrome	5.66e-05	0.0101	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—NR3C1—polycystic ovary syndrome	4.99e-05	0.00886	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP19A1—polycystic ovary syndrome	4.74e-05	0.00843	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—NR3C1—polycystic ovary syndrome	4.06e-05	0.00722	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP1A1—polycystic ovary syndrome	3.69e-05	0.00656	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP1A1—polycystic ovary syndrome	3.49e-05	0.0062	CrCbGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PLAT—polycystic ovary syndrome	1.47e-05	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	1.46e-05	0.000121	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—PGR—polycystic ovary syndrome	1.46e-05	0.000121	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NMNAT3—polycystic ovary syndrome	1.43e-05	0.000119	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	1.43e-05	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—YAP1—polycystic ovary syndrome	1.43e-05	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	1.42e-05	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—GAB1—polycystic ovary syndrome	1.41e-05	0.000117	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ATF1—polycystic ovary syndrome	1.4e-05	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—INHBB—polycystic ovary syndrome	1.39e-05	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	1.37e-05	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.37e-05	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	1.37e-05	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MTHFR—polycystic ovary syndrome	1.35e-05	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—GNAS—polycystic ovary syndrome	1.35e-05	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—INSR—polycystic ovary syndrome	1.34e-05	0.000111	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	1.34e-05	0.000111	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—CYP19A1—polycystic ovary syndrome	1.33e-05	0.00011	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—SERPINE1—polycystic ovary syndrome	1.33e-05	0.00011	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—IL6—polycystic ovary syndrome	1.31e-05	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	1.31e-05	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—LPCAT2—polycystic ovary syndrome	1.31e-05	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SUOX—polycystic ovary syndrome	1.31e-05	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—NCOR1—polycystic ovary syndrome	1.3e-05	0.000108	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PDE3B—polycystic ovary syndrome	1.3e-05	0.000108	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	1.3e-05	0.000107	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	1.29e-05	0.000107	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NGFR—polycystic ovary syndrome	1.29e-05	0.000107	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—IRS2—polycystic ovary syndrome	1.29e-05	0.000107	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—YAP1—polycystic ovary syndrome	1.29e-05	0.000107	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—NCOR1—polycystic ovary syndrome	1.28e-05	0.000106	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PRL—polycystic ovary syndrome	1.28e-05	0.000106	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.28e-05	0.000106	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKR1C2—polycystic ovary syndrome	1.27e-05	0.000105	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TEAD2—polycystic ovary syndrome	1.27e-05	0.000105	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—YAP1—polycystic ovary syndrome	1.27e-05	0.000105	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.26e-05	0.000104	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	1.22e-05	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ISYNA1—polycystic ovary syndrome	1.22e-05	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CYP1A1—polycystic ovary syndrome	1.22e-05	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.21e-05	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Biological oxidations—POMC—polycystic ovary syndrome	1.21e-05	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—NR3C1—polycystic ovary syndrome	1.2e-05	9.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	1.2e-05	9.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	1.19e-05	9.86e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FSHR—polycystic ovary syndrome	1.18e-05	9.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—IL6—polycystic ovary syndrome	1.18e-05	9.76e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PLAT—polycystic ovary syndrome	1.16e-05	9.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—GHRL—polycystic ovary syndrome	1.16e-05	9.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—PPARG—polycystic ovary syndrome	1.14e-05	9.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	1.14e-05	9.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—TNRC6B—polycystic ovary syndrome	1.14e-05	9.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—MTHFR—polycystic ovary syndrome	1.13e-05	9.4e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—GNAS—polycystic ovary syndrome	1.13e-05	9.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—IRS1—polycystic ovary syndrome	1.12e-05	9.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PGR—polycystic ovary syndrome	1.12e-05	9.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—PPARG—polycystic ovary syndrome	1.12e-05	9.28e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—TNRC6B—polycystic ovary syndrome	1.12e-05	9.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	1.11e-05	9.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	1.11e-05	9.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PGR—polycystic ovary syndrome	1.11e-05	9.18e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ATF1—polycystic ovary syndrome	1.1e-05	9.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	1.08e-05	8.97e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—INS—polycystic ovary syndrome	1.08e-05	8.93e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.08e-05	8.93e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	1.07e-05	8.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.07e-05	8.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PNPLA2—polycystic ovary syndrome	1.07e-05	8.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	1.06e-05	8.78e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FST—polycystic ovary syndrome	1.05e-05	8.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	1.05e-05	8.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NRG1—polycystic ovary syndrome	1.05e-05	8.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ADRB3—polycystic ovary syndrome	1.04e-05	8.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—AKT2—polycystic ovary syndrome	1.04e-05	8.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TEAD2—polycystic ovary syndrome	1.04e-05	8.58e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKR1C2—polycystic ovary syndrome	1.04e-05	8.58e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—LHB—polycystic ovary syndrome	1.03e-05	8.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—SERPINE1—polycystic ovary syndrome	1.02e-05	8.49e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NGFR—polycystic ovary syndrome	1.02e-05	8.45e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SRD5A1—polycystic ovary syndrome	1.01e-05	8.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PRL—polycystic ovary syndrome	1.01e-05	8.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—SERPINE1—polycystic ovary syndrome	1.01e-05	8.36e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GNRH1—polycystic ovary syndrome	1.01e-05	8.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	9.95e-06	8.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—NCOR1—polycystic ovary syndrome	9.92e-06	8.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—SERPINE1—polycystic ovary syndrome	9.89e-06	8.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	9.8e-06	8.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	9.74e-06	8.07e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SCT—polycystic ovary syndrome	9.64e-06	7.99e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—STAR—polycystic ovary syndrome	9.64e-06	7.99e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.58e-06	7.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	9.53e-06	7.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	9.44e-06	7.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—PPARG—polycystic ovary syndrome	9.33e-06	7.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	9.2e-06	7.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PPARG—polycystic ovary syndrome	9.2e-06	7.62e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—NR3C1—polycystic ovary syndrome	9.18e-06	7.61e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—POMC—polycystic ovary syndrome	9.07e-06	7.52e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FGF18—polycystic ovary syndrome	9.04e-06	7.49e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IRS2—polycystic ovary syndrome	9.02e-06	7.48e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—INS—polycystic ovary syndrome	9.02e-06	7.48e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RBP4—polycystic ovary syndrome	8.97e-06	7.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—GNAS—polycystic ovary syndrome	8.89e-06	7.36e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—LEP—polycystic ovary syndrome	8.83e-06	7.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—AR—polycystic ovary syndrome	8.74e-06	7.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PNPLA2—polycystic ovary syndrome	8.68e-06	7.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	8.64e-06	7.16e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	8.64e-06	7.16e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—AR—polycystic ovary syndrome	8.61e-06	7.14e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HMMR—polycystic ovary syndrome	8.59e-06	7.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.47e-06	7.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—SERPINE1—polycystic ovary syndrome	8.41e-06	6.97e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—YAP1—polycystic ovary syndrome	8.37e-06	6.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NRG1—polycystic ovary syndrome	8.31e-06	6.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GAB1—polycystic ovary syndrome	8.26e-06	6.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SRD5A1—polycystic ovary syndrome	8.22e-06	6.82e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HSD3B1—polycystic ovary syndrome	8.2e-06	6.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	8.1e-06	6.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	8.03e-06	6.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	8e-06	6.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—INSR—polycystic ovary syndrome	7.89e-06	6.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IRS1—polycystic ovary syndrome	7.88e-06	6.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—STAR—polycystic ovary syndrome	7.85e-06	6.5e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	7.76e-06	6.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	7.68e-06	6.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—NCOR1—polycystic ovary syndrome	7.64e-06	6.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—POMC—polycystic ovary syndrome	7.59e-06	6.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—INS—polycystic ovary syndrome	7.54e-06	6.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—NCOR1—polycystic ovary syndrome	7.53e-06	6.24e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	7.5e-06	6.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—LHB—polycystic ovary syndrome	7.48e-06	6.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	7.38e-06	6.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PGR—polycystic ovary syndrome	7.31e-06	6.06e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HSD3B2—polycystic ovary syndrome	7.31e-06	6.06e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IGF1—polycystic ovary syndrome	7.3e-06	6.05e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—AKT2—polycystic ovary syndrome	7.29e-06	6.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IRS2—polycystic ovary syndrome	7.12e-06	5.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—PPARG—polycystic ovary syndrome	7.11e-06	5.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKR1C1—polycystic ovary syndrome	7.08e-06	5.86e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—NR3C1—polycystic ovary syndrome	7.07e-06	5.86e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HMMR—polycystic ovary syndrome	6.99e-06	5.8e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—LEP—polycystic ovary syndrome	6.96e-06	5.77e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.93e-06	5.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	6.83e-06	5.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	6.83e-06	5.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PLAT—polycystic ovary syndrome	6.79e-06	5.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GHRL—polycystic ovary syndrome	6.79e-06	5.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	6.67e-06	5.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	6.59e-06	5.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SULT2A1—polycystic ovary syndrome	6.51e-06	5.4e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ATF1—polycystic ovary syndrome	6.48e-06	5.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—SERPINE1—polycystic ovary syndrome	6.4e-06	5.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.32e-06	5.24e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—RRM2—polycystic ovary syndrome	6.31e-06	5.23e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	6.25e-06	5.18e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IRS1—polycystic ovary syndrome	6.21e-06	5.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	6.08e-06	5.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	6.08e-06	5.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—POMC—polycystic ovary syndrome	5.98e-06	4.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NGFR—polycystic ovary syndrome	5.98e-06	4.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—INS—polycystic ovary syndrome	5.95e-06	4.93e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	5.95e-06	4.93e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PRL—polycystic ovary syndrome	5.93e-06	4.91e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	5.84e-06	4.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	5.81e-06	4.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	5.77e-06	4.78e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	5.76e-06	4.77e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IGF1—polycystic ovary syndrome	5.76e-06	4.77e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—AKT2—polycystic ovary syndrome	5.75e-06	4.77e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	5.73e-06	4.75e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	5.72e-06	4.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.62e-06	4.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PPARG—polycystic ovary syndrome	5.48e-06	4.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.47e-06	4.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	5.45e-06	4.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	5.42e-06	4.5e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PPARG—polycystic ovary syndrome	5.39e-06	4.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	5.36e-06	4.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	5.3e-06	4.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GNAS—polycystic ovary syndrome	5.22e-06	4.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	5.17e-06	4.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	5.13e-06	4.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.97e-06	4.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	4.95e-06	4.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—SERPINE1—polycystic ovary syndrome	4.93e-06	4.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NRG1—polycystic ovary syndrome	4.88e-06	4.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—SERPINE1—polycystic ovary syndrome	4.86e-06	4.03e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.77e-06	3.95e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	4.75e-06	3.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	4.73e-06	3.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—IL6—polycystic ovary syndrome	4.71e-06	3.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	4.69e-06	3.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	4.66e-06	3.86e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TH—polycystic ovary syndrome	4.64e-06	3.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	4.61e-06	3.82e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	4.51e-06	3.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	4.43e-06	3.67e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	4.4e-06	3.65e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	4.36e-06	3.62e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	4.24e-06	3.52e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IRS2—polycystic ovary syndrome	4.18e-06	3.46e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—LEP—polycystic ovary syndrome	4.09e-06	3.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	4.01e-06	3.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	3.92e-06	3.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	3.8e-06	3.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	3.79e-06	3.14e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TH—polycystic ovary syndrome	3.78e-06	3.13e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.76e-06	3.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	3.67e-06	3.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IRS1—polycystic ovary syndrome	3.65e-06	3.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	3.61e-06	2.99e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—POMC—polycystic ovary syndrome	3.51e-06	2.91e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	3.5e-06	2.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—INS—polycystic ovary syndrome	3.49e-06	2.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	3.45e-06	2.86e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	3.42e-06	2.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	3.39e-06	2.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.38e-06	2.8e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.38e-06	2.8e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL6—polycystic ovary syndrome	3.3e-06	2.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	3.26e-06	2.7e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.21e-06	2.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	3.19e-06	2.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	3.14e-06	2.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	3.1e-06	2.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	3.08e-06	2.56e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	2.94e-06	2.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	2.92e-06	2.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	2.88e-06	2.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	2.78e-06	2.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL6—polycystic ovary syndrome	2.6e-06	2.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	2.6e-06	2.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	2.59e-06	2.14e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	2.55e-06	2.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—INS—polycystic ovary syndrome	2.54e-06	2.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TH—polycystic ovary syndrome	2.49e-06	2.06e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	2.42e-06	2.01e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	2.28e-06	1.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.21e-06	1.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	2.1e-06	1.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	2.08e-06	1.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—INS—polycystic ovary syndrome	2.06e-06	1.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.03e-06	1.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.94e-06	1.61e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.84e-06	1.52e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.71e-06	1.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL6—polycystic ovary syndrome	1.53e-06	1.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.39e-06	1.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.37e-06	1.13e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.36e-06	1.13e-05	CbGpPWpGaD
